Search hospitals
>
California
>
Duarte
City of Hope Comprehensive Cancer Center
Claim this profile
Duarte, California 91010
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Lymphoma
Conducts research for Solid Tumors
2114 reported clinical trials
157 medical researchers
Summary
City of Hope Comprehensive Cancer Center is a medical facility located in Duarte, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Lymphoma, Solid Tumors and other specialties. City of Hope Comprehensive Cancer Center is involved with conducting 2,114 clinical trials across 1,167 conditions. There are 157 research doctors associated with this hospital, such as Daneng Li, MD, Anna Pawlowska, MD, Mark Agulnik, and Vincent Chung, MD.
Area of expertise
Cancer
City of Hope Comprehensive Cancer Center has run 382 trials for Cancer. Some of their research focus areas include:
Lung Cancer
City of Hope Comprehensive Cancer Center has run 267 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Daneng Li, MD
City of Hope
6 years of reported clinical research
Anna Pawlowska, MD
City of Hope Comprehensive Cancer Center
8 years of reported clinical research
Mark Agulnik
City of Hope
3 years of reported clinical research
Vincent Chung, MD
City of Hope Medical Center
3 years of reported clinical research
Clinical Trials running at City of Hope Comprehensive Cancer Center
Prostate Cancer
Breast Cancer
Skin Cancer
Breast cancer
Kidney Cancer
Cancer
Lung Cancer
Pancreatic Cancer
Multiple Myeloma
Testicular cancer
Ifinatamab Deruxtecan
for Prostate Cancer
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,
Recruiting
2 awards
Phase 3
2 criteria
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting
2 awards
Phase 3
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting
2 awards
Phase 3
30 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at City of Hope Comprehensive Cancer Center?
City of Hope Comprehensive Cancer Center is a medical facility located in Duarte, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Lymphoma, Solid Tumors and other specialties. City of Hope Comprehensive Cancer Center is involved with conducting 2,114 clinical trials across 1,167 conditions. There are 157 research doctors associated with this hospital, such as Daneng Li, MD, Anna Pawlowska, MD, Mark Agulnik, and Vincent Chung, MD.
Where is City of Hope Comprehensive Cancer Center located?
**City of Hope Comprehensive Cancer Center** - **Location:** 1500 E Duarte Rd, Duarte, CA - **Accessibility:** Conveniently accessible from the 210 Freeway, near the intersection of Duarte Road and Royal Oaks Drive.
Who should I call to ask about financial aid or insurance network?
**City of Hope Comprehensive Cancer Center Financial and Insurance Assistance Services:** - **Financial Counselors:** Offer financial counseling, benefits explanation, out-of-pocket cost estimates, insurance authorization, and medical necessity screening. - **Patient Resource Coordinator:** Provides financial assistance, transportation, healthcare referrals. Contact: 626-256-4673, ext. 32273. - **Clinical Social Workers:** Assist with financial benefit guidance, including state and social security disability, and paid family leave benefits. - **Sheri & Les Biller Patient and Family Resource Center:** A central hub for support services, offering resources to empower patients throughout their treatment. - **Cancer Legal Resource Center (CLRC):** Offers education and support on employment, healthcare access, government benefits, medical leave, and estate planning. **Financial Assistance Application:** Patients can apply for financial assistance at any stage of their treatment. The application process involves completing a Financial Evaluation Form with the help of Financial Support Services Counselors and submitting necessary documentation. Pre-screening requests can be made by calling (844) 936-4673. Applications can also be initiated via the patient portal.
What insurance does City of Hope Comprehensive Cancer Center accept?
The City of Hope Comprehensive Cancer Center accepts a variety of insurance plans, including PPO, Covered California, HMO, and Medicare. For Covered California, it accepts Blue Shield of California EPO/PPO and OSCAR Health Plan of California EPO at all levels for services at their clinical network locations, though OSCAR Health Plan - City of Hope Medical Center in Duarte is out-of-network. For accurate estimates, contact their financial counselors at (833) 915-4673.
What awards or recognition has City of Hope Comprehensive Cancer Center received?
City of Hope Comprehensive Cancer Center, located in Duarte, California, is a National Cancer Institute-designated comprehensive cancer center, recognized for its excellence in cancer treatment, research, and expertise. It is a founding member of the National Comprehensive Cancer Network, showcasing its leadership in cancer research and treatment advancements. Consistently ranked among the top cancer centers in the United States by U.S. News & World Report, it has secured a position in the top 10 for the past two years.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.